Everest Medicines

News

23 2021/08

Everest Medicines to Announce Half-Year 2021 Interim Results
05 2021/08

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava^TM for Community-Acquired Bacterial Pneumonia
29 2021/07

Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
20 2021/07

Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
13 2021/07

Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China
12 2021/07

Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent
05 2021/07

Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
20 2021/05

Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer
17 2021/05

Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
06 2021/05

Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
15 2021/04

Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
14 2021/04

Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy^® for the Treatment of Metastatic Urothelial Cancer

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号